📰 Liminal Bioscience News
Page 6 - Liminal Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Liminal Bioscience. Real-time updates on events, politics, business and more.
July 21, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of...
June 6, 2022
LAVAL, QC and CAMBRIDGE, England, June 6, 2022 /PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General
June 6, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of...
May 23, 2022
LAVAL, QC and CAMBRIDGE, England, May 23, 2022 /PRNewswire/ -- Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been
May 10, 2022
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple
May 10, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the first quarter...
May 10, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the first quarter...
May 9, 2022
/PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022...
May 9, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that...
May 9, 2022
LAVAL, QC and CAMBRIDGE, ENGLAND, May 9, 2022 /PRNewswire/ -- Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first